
    
      This study is a phase 3, multicenter, randomized, double-blinded, placebo-controlled,
      parallel-group study to examine the efficacy, safety, and pharmacokinetics of MLN0002
      (Vedolizumab) in induction and maintenance therapy in Japanese patients with moderately or
      severely active ulcerative colitis.
    
  